Horama SAS has raised €19m ($22m) in a series B funding round led by Fundplus, Pontifax Ltd, and IDInvest Partners.
The French clinical-stage biotechnology company plans to use the funds towards the development of gene therapy treatments for rare retinal diseases.
Go deeper with GlobalData
US-based biotechnology company Fibrocell Science Inc plans to raise $23m in a public offering of shares of its common stock.
Underwriters have a 30-day option to purchase additional shares to cover over-allotments if any.
Sensus Healthcare Inc plans to raise $20m through a public offering of shares of its common stock, preferred stock, warrants, stock purchase contracts and other securities.
The US-based medical technology company proposes to use the funds for general corporate purposes including the repurchase of common stock and financing of possible acquisitions.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataVoyager Therapeutics Inc plans to issue four million shares priced at $12 a share to raise $62.1m.
The US-based clinical-stage company plans to use the funds for pre-clinical and clinical development activities and other general corporate purposes.
Swiss oncology company Nouscom AG has raised €42m ($48.79m) in a series B funding round led by Abingworth LLP.
The company plans to use the funds to advance the development of its cancer vaccine NOUS-209.
